Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Abela

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
AIDS (London, England)|July 25, 2022
Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIVFrédérique Chammartin, Katharina Kusejko, Chloé Pasin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled TrialBenjamin Speich, Frédérique Chammartin, Irene A Abela, et al.
The Journal of Clinical Investigation|April 28, 2022
Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody responseMaddalena Marconato, Irene A Abela, Anthony Hauser, et al.
Trials|October 22, 2021
A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®Benjamin Speich, Frédérique Chammartin, Daniel Smith, et al.
Eclinicalmedicine|January 22, 2026
Cancer burden and risk factors among women with HIV: a multi-regional study from the D:A:D and RESPOND cohort collaborationsWin Min Han, Bastian Neesgaard, Michael Knappik, et al.
Mbio|January 25, 2024
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infectionIrene A Abela, Magdalena Schwarzmüller, Agne Ulyte, et al.
Plos One|January 24, 2025
Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune functionAnnette Audigé, Alain Amstutz, Macé M Schuurmans, et al.
Open Forum Infectious Diseases|April 10, 2023
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)Alexandra Griessbach, Frédérique Chammartin, Irene A Abela, et al.
The Journal of Infectious Diseases|January 16, 2024
Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort StudyIrene A Abela, Anthony Hauser, Magdalena Schwarzmüller, et al.
Tobacco Induced Diseases|May 28, 2026
Acceptance and preferences for different nicotine substitute products to reduce tobacco smoking in people living with HIV: Results from an internal pilot study of a randomized trialChristof M Schönenberger, Stephanie Campos Ochoa, Benjamin Speich, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
AIDS (London, England)|July 25, 2022
Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIVFrédérique Chammartin, Katharina Kusejko, Chloé Pasin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled TrialBenjamin Speich, Frédérique Chammartin, Irene A Abela, et al.
The Journal of Clinical Investigation|April 28, 2022
Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody responseMaddalena Marconato, Irene A Abela, Anthony Hauser, et al.
Trials|October 22, 2021
A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®Benjamin Speich, Frédérique Chammartin, Daniel Smith, et al.
Eclinicalmedicine|January 22, 2026
Cancer burden and risk factors among women with HIV: a multi-regional study from the D:A:D and RESPOND cohort collaborationsWin Min Han, Bastian Neesgaard, Michael Knappik, et al.
Mbio|January 25, 2024
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infectionIrene A Abela, Magdalena Schwarzmüller, Agne Ulyte, et al.
Plos One|January 24, 2025
Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune functionAnnette Audigé, Alain Amstutz, Macé M Schuurmans, et al.
Open Forum Infectious Diseases|April 10, 2023
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)Alexandra Griessbach, Frédérique Chammartin, Irene A Abela, et al.
The Journal of Infectious Diseases|January 16, 2024
Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort StudyIrene A Abela, Anthony Hauser, Magdalena Schwarzmüller, et al.
Tobacco Induced Diseases|May 28, 2026
Acceptance and preferences for different nicotine substitute products to reduce tobacco smoking in people living with HIV: Results from an internal pilot study of a randomized trialChristof M Schönenberger, Stephanie Campos Ochoa, Benjamin Speich, et al.
Pageof 7